Abstract
The development of echo contrast agents that can provide reliable opacification of the myocardium after intravenous injection is an important advancement for the clinical application of contrast echocardiography. In this study, the hemodynamic effects and echocardiographic characteristics of a new lipid-fluorocarbon echo contrast agent, Aerosomes MRX 115 (ImaRx Pharmaceutical Corp., Tucson, Ariz.) were studied in six anesthetized ventilated pigs. Intravenous injection of this new agent in doses ranging from 0.0005 to 0.01 ml/kg produced significant measurable and visible myocardial opacification without any effect on heart rate, systemic pressure, partial pressure of oxygen, or left ventricular systolic function. The two largest doses (0.005 and 0.01 ml/kg), however, resulted in mild reversible increases in mean pulmonary artery pressure of 12 and 16 mm Hg, respectively. In four animals, epicardial images were obtained before and during coronary artery occlusion. Intravenous contrast injection during coronary occlusion permitted delineation of the hypoperfused myocardial segment. This capability may further expand the utility of contrast echocardiography.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 938-945 |
| Number of pages | 8 |
| Journal | American Heart Journal |
| Volume | 132 |
| Issue number | 5 |
| DOIs | |
| State | Published - 1996 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Myocardial imaging with a new transpulmonary lipid-fluorocarbon echo contrast agent : Experimental studies in pigs. / Grauer, Susan E.; Pantely, George; Xu, Jinping; Ge, Shuping; Giraud, George; Shiota, Takahiro; Sahn, David.
In: American Heart Journal, Vol. 132, No. 5, 1996, p. 938-945.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Myocardial imaging with a new transpulmonary lipid-fluorocarbon echo contrast agent
T2 - Experimental studies in pigs
AU - Grauer, Susan E.
AU - Pantely, George
AU - Xu, Jinping
AU - Ge, Shuping
AU - Giraud, George
AU - Shiota, Takahiro
AU - Sahn, David
PY - 1996
Y1 - 1996
N2 - The development of echo contrast agents that can provide reliable opacification of the myocardium after intravenous injection is an important advancement for the clinical application of contrast echocardiography. In this study, the hemodynamic effects and echocardiographic characteristics of a new lipid-fluorocarbon echo contrast agent, Aerosomes MRX 115 (ImaRx Pharmaceutical Corp., Tucson, Ariz.) were studied in six anesthetized ventilated pigs. Intravenous injection of this new agent in doses ranging from 0.0005 to 0.01 ml/kg produced significant measurable and visible myocardial opacification without any effect on heart rate, systemic pressure, partial pressure of oxygen, or left ventricular systolic function. The two largest doses (0.005 and 0.01 ml/kg), however, resulted in mild reversible increases in mean pulmonary artery pressure of 12 and 16 mm Hg, respectively. In four animals, epicardial images were obtained before and during coronary artery occlusion. Intravenous contrast injection during coronary occlusion permitted delineation of the hypoperfused myocardial segment. This capability may further expand the utility of contrast echocardiography.
AB - The development of echo contrast agents that can provide reliable opacification of the myocardium after intravenous injection is an important advancement for the clinical application of contrast echocardiography. In this study, the hemodynamic effects and echocardiographic characteristics of a new lipid-fluorocarbon echo contrast agent, Aerosomes MRX 115 (ImaRx Pharmaceutical Corp., Tucson, Ariz.) were studied in six anesthetized ventilated pigs. Intravenous injection of this new agent in doses ranging from 0.0005 to 0.01 ml/kg produced significant measurable and visible myocardial opacification without any effect on heart rate, systemic pressure, partial pressure of oxygen, or left ventricular systolic function. The two largest doses (0.005 and 0.01 ml/kg), however, resulted in mild reversible increases in mean pulmonary artery pressure of 12 and 16 mm Hg, respectively. In four animals, epicardial images were obtained before and during coronary artery occlusion. Intravenous contrast injection during coronary occlusion permitted delineation of the hypoperfused myocardial segment. This capability may further expand the utility of contrast echocardiography.
UR - http://www.scopus.com/inward/record.url?scp=0029826145&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029826145&partnerID=8YFLogxK
U2 - 10.1016/S0002-8703(96)90002-2
DO - 10.1016/S0002-8703(96)90002-2
M3 - Article
C2 - 8892764
AN - SCOPUS:0029826145
VL - 132
SP - 938
EP - 945
JO - American Heart Journal
JF - American Heart Journal
SN - 0002-8703
IS - 5
ER -